ASML is recovering ground it couldn't hold after earnings — up 4.8% Tuesday to €1,593.40, closing in on the pre-drift levels that defined the frustrating post-results week.
The recovery is the central tension here. A week ago, the July 20 note flagged the "gap" between a genuine Q2 beat, a guidance raise to ~€45 billion in full-year revenue, and a stock that had slipped back below pre-earnings levels. That gap has started to narrow. The Amsterdam shares are now up 2.4% on the week, retracing the decline from the July 17 close of €1,537. The move is not coming from short covering — there is nothing to cover. Short interest remains structurally irrelevant, the borrow market is as loose as it gets, and the ORTEX short score at 25.1 ranks in the 97th percentile for absence of bearish positioning. This is a pure re-rating story, driven entirely by fundamental reassessment.
The peer group adds context. Tuesday's session saw broad semiconductor equipment strength across the board. LRCX jumped 5.0% on the day. AMAT surged 7.4%. added 4.8%. rose 5.3%. On a one-week basis, however, those same peers remain sharply lower — LRCX is down nearly 7%, AMAT off 5.2%, KLAC down 5.6% — suggesting Tuesday's rally is a sector-wide snapback rather than ASML-specific momentum. ASML's week-on-week gain of 2.4% therefore represents relative outperformance, not just participation in a rising tide.
Positioning remains entirely one-sided toward conviction longs. Availability is effectively uncapped — over 160 million shares available to borrow — and cost to borrow has edged back up to 0.65% from a recent low of 0.46% on July 9, but remains well within the low range that has characterised this name for months. The institutional register is stable: BlackRock holds 7.2% and added 336,000 shares in the last reported period. Fidelity, Capital Research, and Amundi all added modestly. There are no large holders trimming. The factor score picture is consistent with a name where the bears have stepped away entirely: the short score ranks in the 97th percentile for low bearish activity, and the days-to-cover rank is in the 88th percentile.
The valuation story is the one worth watching. The trailing PE has compressed from the stretched readings of recent weeks — down roughly 10 points over the past 30 days to 35.3x — while the EV/EBITDA multiple has also eased from its highs. That compression is a function of the stock drifting while earnings estimates moved higher post-results. The analyst target stack — JP Morgan at $2,400, Wells Fargo at $2,500, raised in the immediate aftermath of results — implies substantial implied upside from current levels, though those targets are denominated in USD and apply to the Nasdaq-listed shares; the Amsterdam quote at €1,593 and the USD equivalent should be reconciled carefully by readers before anchoring to those levels. The note from July 20 characterised the core question as whether the €1 trillion company narrative takes hold; Tuesday's move nudges that conversation forward without resolving it.
The next scheduled catalyst is Q3 earnings on October 14 — a long runway from here, which means the weeks ahead become a test of whether the fundamental re-rating argument attracts fresh institutional buying or whether the stock continues its pattern of strong results followed by patient drift.
See the live data behind this article on ORTEX.
Open ASML on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
